The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure

Year 2022, Volume: 11 Issue: 3, 337 - 336, 30.12.2022

Lütfü Aşkın , Okan Tanrıverdi

https://doi.org/10.47493/abantmedj.1182158

Cited By: 4

Abstract

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. The development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Sacubitril/valsartan reduces mortality and hospitalization and rehospitalization rates for HF compared with enalapril. In HF patients, sacubitril or valsartan may provide significant benefit.

Keywords

Heart Failure, Natriuretic Peptide, Sacubitril/Valsartan

Düşük Ejeksiyon Fraksiyonu ile Kalp Yetmezliğinde Sakubitril-Valsartanın Faydaları

Abstract

Kalp yetmezliği (KY), perifere yetersiz kan akışı nedeniyle egzersiz kapasitesinin bozulmasının nedenidir. Neprilisin enziminin inhibisyonu yoluyla natriüretik peptit (NP) geliştirmesi, KY' deki terapötik hedeftir. Sakubitril/valsartan, enalapril ile karşılaştırıldığında KY için mortalite ve hastaneye yatış ve yeniden hastaneye yatış oranlarını azaltır. Sakubitril/valsartan KY hastalarında önemli fayda sağlayabilir.

Keywords

Kalp Yetmezliği, Natriüretik Peptit, Sakubitril/Valsartan, Heart Failure, Natriuretic Peptide, Sacubitril/Valsartan

References

• 1- Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23:352-80.
• 2- Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 2020;141:e139-e596.
• 3- D'Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 2017;19:710-7.
• 4- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
• 5- Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol 2017;14:171-86.
• 6- Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med 2019;380:1090.
• 7- Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;77:772-810.
• 8- McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol 2021;37:531-46.
• 9- Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, et al. Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med 2021;8:754499.
• 10- de Diego C, González-Torres L, Núñez JM, Centurión Inda R, Martin-Langerwerf DA, Sangio AD, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm 2018;15:395-402.
• 11- Packer M. Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator. Circ Arrhythm Electrophysiol. 2019;12:e007430.
• 12- Sarrias A, Bayes-Genis A. Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug? Circulation 2018;138:551-3.
• 13- Burke RM, Lighthouse JK, Mickelsen DM, Small EM. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts. Circ Heart Fail 2019;12:e005565.
• 14- Chun S, Tu JV, Wijeysundera HC, Wang X, Levy D, Lee DS. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail 2012;5:414-21.
• 15- Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, et al. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail 2016;4:816-22.
• 16- Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, et al. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation 2016;133:2254-62.
• 17- Murphy SP, Prescott MF, Camacho A, Iyer SR, Maisel AS, Felker GM, et al. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2021;9:127-36.
• 18- Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 2019;322:1077-84.
• 19- Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther 2018;36:e12435.
• 20- Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail 2021;23:1040-8.
• 21- Correale M, Mallardi A, Mazzeo P, Tricarico L, Diella C, Romano V, et al. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry. Int J Cardiol Heart Vasc 2020;27:100486.
• 22- Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc 2019;8:e012272.
• 23- Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-66.
• 24- Judge P, Haynes R, Landray MJ, Baigent C. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant 2015;30:738-43.
• 25- Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail 2017;19:167-76.
• 26- de la Espriella R, Bayés-Genís A, Morillas H, Bravo R, Vidal V, Núñez E, et al. Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes. ESC Heart Fail 2020;7:3792–800.
• 27- Formiga F, Camafort M, Carrasco Sánchez FJ. Heart failure and diabetes: The confrontation of two major epidemics of the 21st century. Rev Clin Esp (Barc) 2020;220:135-8.
• 28- Esser N, Zraika S. Neprilysin inhibition: a new therapeutic option for type 2 diabetes? Diabetologia 2019;62:1113-22.
• 29- McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381:1995-2008.
• 30- Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413-24.
• 31- Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL, et al. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail 2018;20:514-522.
• 32- Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol 2018;3:498-505.
• 33- Vitale G, Romano G, Di Franco A, Caccamo G, Nugara C, Ajello L, et al. Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction. J Clin Med 2019;8:262.
• 34- Vicent L, Esteban-Fernández A, Gómez-Bueno M, De-Juan J, Díez-Villanueva P, Iniesta ÁM, et al. Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial. J Cardiovasc Pharmacol 2018;72:112-6.
• 35- Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, et al. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol 2017;2:79-85.
• 36- Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 2016;18:1193-202.
• 37- Nielsen EE, Feinberg JB, Bu FL, Hecht Olsen M, Raymond I, Steensgaard-Hansen F, et al. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Open Heart 2020;7:e001294.
• 38- Rezq A, Saad M, El Nozahi M. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol 2021;143:7-13.
• 39- Murphy SP, Prescott MF, Camacho A, Iyer SR, Maisel AS, Felker GM, et al. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2021;9:127-36.
• 40- Robles NR, Campillejo RD, Valladares J, de Vinuesa EG, Villa J, Gervasini G. Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS). Cardiovasc Hematol Agents Med Chem 2021;19:93-7.
• 41- Lee YH, Lin PL, Chiou WR, Huang JL, Lin WY, Liao CT, et al. Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction. ESC Heart Fail 2021;8:1204-15.
• 42- Zandstra TE, Nederend M, Jongbloed MRM, Kiès P, Vliegen HW, Bouma BJ, et al. Sacubitril/valsartan in the treatment of systemic right ventricular failure. Heart 2021;107:1725-30.
• 43- Nie D, Xiong B, Qian J, Rong S, Yao Y, Huang J. The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis. Heart Lung Circ 2021;30:683-91.
• 44- Khan MS, Felker GM, Piña IL, Camacho A, Bapat D, Ibrahim NE, et al. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC Heart Fail 2021;9:137-45.
• 45- Cheng S, Zhang N, Hua W. Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices. Am J Cardiovasc Drugs 2021;21:383-93.
• 46- Piña IL, Camacho A, Ibrahim NE, Felker GM, Butler J, Maisel AS, et al. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. JACC Heart Fail 2021;9:42-51.
• 47- Galo J, Celli D, Colombo R. Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions. Am J Cardiovasc Drugs 2021;21:267-70.
• 48- Martyn T, Faulkenberg KD, Albert CL, Il'giovine ZJ, Randhawa VK, Donnellan E, et al. Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy. J Card Fail 2021;27:368-72.
• 49- Holm N, Bromage DI, Cannata A, DeCourcey J, Bhatti P, Huang M, et al. Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan. J Cardiovasc Med (Hagerstown) 2022;23:37-41.